|
1
|
Parmar MK, Ledermann JA, Colombo N, du
Bois A, Delaloye JF, Kristensen GB, Wheeler S, Swart AM, Qian W,
Torri V, Floriani I, Jayson G, Lamont A and Tropé C; ICON AGO
Collaborators. Paclitaxel plus platinum-based chemotherapy versus
conventional platinum-based chemotherapy in women with relapsed
ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet.
361:2099–2106. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
González-Martin AJ, Calvo E, Bover I,
Rubio MJ, Arcusa A, Casado A, Ojeda B, Balañá C, Martínez E,
Herrero A, Pardo B, Adrover E, Rifá J, Godes MJ, Moyano A and
Cervantes A: Randomized phase II trial of carboplatin versus
paclitaxel and carboplatin in platinum-sensitive recurrent advanced
ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en
Cancer de Ovario) study. Ann Oncol. 16:749–755. 2005.
|
|
3
|
Ozols RF, Bundy BN, Greer BE, Fowler JM,
Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM
and Baergen R; Gynecologic Oncology Group. Phase III trial of
carboplatin and paclitaxel compared with cisplatin and paclitaxel
in patients with optimally resected stage III ovarian cancer: a
Gynecologic Oncology Group study. J Clin Oncol. 21:3194–3200. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Du Bois A, Lück HJ, Meier W, Adams HP,
Möbus V, Costa S, Bauknecht T, Richter B, Warm M, Schröder W,
Olbricht S, Nitz U, Jackisch C, Emons G, Wagner U, Kuhn W and
Pfisterer J; Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian
Cancer Study Group. A randomized clinical trial of
cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line
treatment of ovarian cancer. J Natl Cancer Inst. 95:1320–1329.
2003.PubMed/NCBI
|
|
5
|
Markman M, Kennedy A, Webster K, Elson P,
Peterson G, Kulp B and Belinson J: Clinical features of
hypersensitivity reactions to carboplatin. J Clin Oncol.
17:11411999.PubMed/NCBI
|
|
6
|
Rose PG, Fusco N, Smrekar M, Mossbruger K
and Rodriguez M: Successful administration of carboplatin in
patients with clinically documented carboplatin hypersensitivity.
Gynecol Oncol. 89:429–433. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Confino-Cohen R, Fishman A, Altaras M and
Goldberg A: Successful carboplatin desensitization in patients with
proven carboplatin allergy. Cancer. 104:640–643. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Castells MC, Tennant NM, Sloane DE, Hsu
FI, Barrett NA, Hong DI, Laidlaw TM, Legere HJ, Nallamshetty SN,
Palis RI, Rao JJ, Berlin ST, Campos SM and Matulonis UA:
Hypersensitivity reactions to chemotherapy: outcomes and safety of
rapid desensitization in 413 cases. J Allergy Clin Immunol.
122:574–580. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Markman M, Kennedy A, Webster K, Elson P,
Peterson G, Kulp B and Belinson J: Paclitaxel-associated
hypersensitivity reactions: experience of the gynecologic oncology
program of the Cleveland Clinic Cancer Center. J Clin Oncol.
18:102–105. 2000.
|
|
10
|
Lee CW, Matulonis UA and Castells MC:
Rapid inpatient/outpatient desensitization for chemotherapy
hypersensitivity: standard protocol effective in 57 patients for
255 courses. Gynecol Oncol. 99:393–399. 2005. View Article : Google Scholar
|
|
11
|
McElroy TM, Gruenigen VE and Waggoner SE:
A case of prolonged carboplatin therapy in a patient with
carboplatin hypersensitivity. Gynecol Oncol. 91:435–437. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Navo M, Kunthur A, Badell ML, Coffer LW
II, Markman M, Brown J and Smith JA: Evaluation of the incidence of
carboplatin hypersensitivity reactions in cancer patients. Gynecol
Oncol. 103:608–613. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lee CW, Matulonis UA and Castells MC:
Carboplatin hypersensitivity: a 6-h 12-step protocol effective in
35 desensitizations in patients with malignancies and mast
cell/IgE-mediated reactions. Gynecol Oncol. 95:370–376. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lenz HJ: Management and preparedness for
infusion and hypersensitivity reactions. Oncologist. 12:601–609.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Markman M, Hsieh F, Zanotti K, Webster K,
Peterson G, Kulp B, Spicel A and Belinson J: Initial experience
with a novel desensitization strategy for carboplatin-associated
hypersensitivity reactions: carboplatin-hypersensitivity reactions.
J Cancer Res Clin Oncol. 130:25–28. 2004. View Article : Google Scholar
|
|
16
|
Watanebe Y, Nakai H, Ueda H, Nozaki K and
Hoshiai H: Carboplatin hypersensitivity induced by low-dose
paclitaxel/carboplatin in multiple platinum-treated patients with
recurrent ovarian cancer. Int J Gynecol Cancer. 15:224–227. 2005.
View Article : Google Scholar
|
|
17
|
Shepherd GM: Hypersensitivity reaction to
chemotherapeutic drugs. Clin Rev Allergy Immunol. 24:253–262. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Schwartz JR, Bandera C, Bradley A, Brard
L, Legare R, Granai CO and Dizon DS: Dose the platinum-free
interval predict the incidence or severity of hypersensitivity
reactions to carboplatin? The experience from Women and Infants’
Hospital. Gynecol Oncol. 105:81–83. 2007.PubMed/NCBI
|
|
19
|
McAlpine JN, Kelly MG, O’Malley DM, Azodi
M, Coombe K, Schwartz PE and Rutherford TJ: Atypical presentations
of carboplatin hypersensitivity reactions: characterization and
management in patients with gynecologic malignancies. Gynecol
Oncol. 103:288–292. 2006. View Article : Google Scholar
|
|
20
|
Markman M: The dilemma of
carboplatin-associated hypersensitivity reactions in ovarian cancer
management. Gynecol Oncol. 107:163–165. 2007. View Article : Google Scholar : PubMed/NCBI
|
